NEW YORK (GenomeWeb News) — GATC Biotech will use 454 Life Sciences’ genome sequencing technology for its sequencing and analysis business, GATC said today.
GATC, based in Konstanz, Germany, said that by adapting 454’s technology with traditional Sanger technology it can cut the sequencing and analysis time in half and reduce costs.
The company also said it will use 454’s instrument to sequence whole transcriptomes and for in-depth analyses of rare mutations.
GATC said using 454’s technology has boosted its own sequencing capacity to 15.6 gigabases per year.
Financial terms of the agreement were not disclosed.